REGULATORY ENABLEMENT OF MOLECULAR ENDOTYPES FOR DRUG DEVELOPMENT. DEFINITION OF THE CONTEXT OF USE (COU) AND MOLECULAR ENDOTYPE WHICH MOST URGENTLY WILL ASSIST IN DRUG DEVELOPMENT: STAKEHOLDER ALIGNMENT UNDER THE CLINICAL TRIAL SYMPOSIUM (CTS) & OARSI UMBRELLA
Publication
, Conference
Karsdal, M; Bay-Jensen, AC; Mobasheri, A; Ladel, C; Kraus, VB
Published in: OSTEOARTHRITIS AND CARTILAGE
2024
Duke Scholars
Published In
OSTEOARTHRITIS AND CARTILAGE
EISSN
1522-9653
ISSN
1063-4584
Publication Date
2024
Volume
32
Start / End Page
S125 / S125
Related Subject Headings
- Arthritis & Rheumatology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 1106 Human Movement and Sports Sciences
- 1103 Clinical Sciences
- 0903 Biomedical Engineering
Citation
APA
Chicago
ICMJE
MLA
NLM
Karsdal, M., Bay-Jensen, A. C., Mobasheri, A., Ladel, C., & Kraus, V. B. (2024). REGULATORY ENABLEMENT OF MOLECULAR ENDOTYPES FOR DRUG DEVELOPMENT. DEFINITION OF THE CONTEXT OF USE (COU) AND MOLECULAR ENDOTYPE WHICH MOST URGENTLY WILL ASSIST IN DRUG DEVELOPMENT: STAKEHOLDER ALIGNMENT UNDER THE CLINICAL TRIAL SYMPOSIUM (CTS) & OARSI UMBRELLA. In OSTEOARTHRITIS AND CARTILAGE (Vol. 32, pp. S125–S125).
Karsdal, Morten, Anne C. Bay-Jensen, Ali Mobasheri, Christoph Ladel, and Virginia B. Kraus. “REGULATORY ENABLEMENT OF MOLECULAR ENDOTYPES FOR DRUG DEVELOPMENT. DEFINITION OF THE CONTEXT OF USE (COU) AND MOLECULAR ENDOTYPE WHICH MOST URGENTLY WILL ASSIST IN DRUG DEVELOPMENT: STAKEHOLDER ALIGNMENT UNDER THE CLINICAL TRIAL SYMPOSIUM (CTS) & OARSI UMBRELLA.” In OSTEOARTHRITIS AND CARTILAGE, 32:S125–S125, 2024.
Karsdal M, Bay-Jensen AC, Mobasheri A, Ladel C, Kraus VB. REGULATORY ENABLEMENT OF MOLECULAR ENDOTYPES FOR DRUG DEVELOPMENT. DEFINITION OF THE CONTEXT OF USE (COU) AND MOLECULAR ENDOTYPE WHICH MOST URGENTLY WILL ASSIST IN DRUG DEVELOPMENT: STAKEHOLDER ALIGNMENT UNDER THE CLINICAL TRIAL SYMPOSIUM (CTS) & OARSI UMBRELLA. In: OSTEOARTHRITIS AND CARTILAGE. 2024. p. S125–S125.
Karsdal, Morten, et al. “REGULATORY ENABLEMENT OF MOLECULAR ENDOTYPES FOR DRUG DEVELOPMENT. DEFINITION OF THE CONTEXT OF USE (COU) AND MOLECULAR ENDOTYPE WHICH MOST URGENTLY WILL ASSIST IN DRUG DEVELOPMENT: STAKEHOLDER ALIGNMENT UNDER THE CLINICAL TRIAL SYMPOSIUM (CTS) & OARSI UMBRELLA.” OSTEOARTHRITIS AND CARTILAGE, vol. 32, 2024, pp. S125–S125.
Karsdal M, Bay-Jensen AC, Mobasheri A, Ladel C, Kraus VB. REGULATORY ENABLEMENT OF MOLECULAR ENDOTYPES FOR DRUG DEVELOPMENT. DEFINITION OF THE CONTEXT OF USE (COU) AND MOLECULAR ENDOTYPE WHICH MOST URGENTLY WILL ASSIST IN DRUG DEVELOPMENT: STAKEHOLDER ALIGNMENT UNDER THE CLINICAL TRIAL SYMPOSIUM (CTS) & OARSI UMBRELLA. OSTEOARTHRITIS AND CARTILAGE. 2024. p. S125–S125.
Published In
OSTEOARTHRITIS AND CARTILAGE
EISSN
1522-9653
ISSN
1063-4584
Publication Date
2024
Volume
32
Start / End Page
S125 / S125
Related Subject Headings
- Arthritis & Rheumatology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 1106 Human Movement and Sports Sciences
- 1103 Clinical Sciences
- 0903 Biomedical Engineering